Nanjing Synnocare Pharmaceutical Technology Co., Ltd. focuses on unmet clinical needs and targets that are difficult to develop drugs. In malignancies and autoimmune diseases fields, we integrate AI and multi-omics technology into the whole process of new drug development from target discovery to drug molecule design and clinical trial design. The indirect targeting strategy of synthetic lethal and RNA small molecules provides a new way for the development of difficult drug targets and new molecules. We are committed to developing original new small molecule drugs with global intellectual property rights.
Leading-edge Pipeline
R&D Staff
R&D Functions
Staff with Master or Doctoral Degrees
Aiming at drug-resistant targets that are not met by clinical needs, indirect targeting strategies are adopted to carefully layout the research directions of "Synthetic lethal" and "Target-RNA small molecules"
